Navigation Links
BD Statement Regarding Impact of Japan Earthquake
Date:3/15/2011

FRANKLIN LAKES, N.J., March 15, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) has operations in Japan led by its Nippon Becton Dickinson headquarters office in Tokyo, and a manufacturing facility and distribution center in Fukushima prefecture.  The Company today confirmed that all of its employees in Japan are safe and that its office in Tokyo is undamaged and functional. BD's manufacturing plant and distribution center in Fukushima are temporarily closed while the Company assesses damage, which does not appear to be extensive.  BD is also in the process of evaluating access to utilities and transportation, which have been impacted throughout Japan due to the earthquake and tsunami. BD sources certain component parts and finished products from third-party suppliers in Japan, and currently believes that inventories of these items will be sufficient to meet global demand until supply chain interruptions are resolved.

Revenues in Japan represented approximately 5 percent of BD's fiscal year 2010 revenues.  Revenues from products manufactured in Japan (BD Hypak™ Prefillable Syringes and prepared plated media) represented approximately 1 percent of BD's fiscal year 2010 revenues.

BD is actively engaged with many disaster relief organizations in supporting the humanitarian aid effort.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com. Contact:Colleen T. White, Corporate Communications – 201-847-5369Zachary A. Nagle, Investor Relations – 201-847-5453
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Assured Pharmacy Completes Audit of 2008-2009 Financial Statements
2. Statement: PILMA Applauds Senate Passage of Patent Reform
3. The FDA Releases a Public Health Statement on Metal-on-Metal Hip Implants
4. Nephros Rights Offering Registration Statement Declared Effective
5. Vanda Pharmaceuticals Files Shelf Registration Statement
6. Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA
7. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
8. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
9. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
10. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
11. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular SearchLight ... online modeling resource for fluorescence microscopists and optical system designers, enabling The Right ... years spanning the globe, SearchLight has become a tremendously popular tool for the ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research Foundation ... A Nudge Guide," a groundbreaking analysis of how behavioral economics can be applied ... immediately to IRR programs, the report highlights proven behavioral economics approaches and the ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
(Date:4/27/2017)... ... ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including three new ... first new location will open at the corner of 27th and Randolph in Lincoln, ... this fall. And the third location is in the process of being identified. ...
Breaking Medicine News(10 mins):